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Abstract (245 words) 24 
Aim To investigate the relationships between six classes of non-medical prescription drug 25 
use (NMPDU) and five personality traits.  26 
Methods Representative baseline data on 5,777 Swiss men around 20 years old were taken 27 
from the Cohort Study on Substance Use Risk Factors. 28 
NMPDU of opioid analgesics, sedatives/sleeping pills, anxiolytics, antidepressants, beta-29 
blockers and stimulants over the previous 12 months was measured. Personality was 30 
assessed using the brief sensation seeking scale; attention-deficit hyperactivity (ADH) using 31 
the adult attention-deficit hyperactivity disorder self-report scale; and aggression/hostility, 32 
anxiety/neuroticism and sociability using the Zuckerman-Kuhlmann personality 33 
questionnaire.  34 
Logistic regression models for each personality trait were fitted, as were seven multiple 35 
logistic regression models predicting each NMPDU adjusting for all personality traits and 36 
covariates. 37 
Results Around 10.7% of participants reported NMPDU in the last 12 months, with opioid 38 
analgesics most prevalent (6.7%), then sedatives/sleeping pills (3.0%), anxiolytics (2.7%), 39 
and stimulants (1.9%). Sensation seeking (SS), ADH, aggressivity/hostility, and 40 
anxiety/neuroticism (but not sociability) were significantly positively associated with at 41 
least one drug class (OR varied between 1.24 [1.04-1.48] and 1.86 [1.47-2.35]). 42 
Aggression/hostility, anxiety/neuroticism and ADH were significantly and positively related 43 
to almost all NMPDU.  44 
Sociability was inversely related to NMPDU of sedatives/sleeping pills and anxiolytics (OR 45 
0.70 [0.51-0.96] and 0.64 [0.46-0.90], respectively).  46 
SS was only related to stimulant use (OR=1.74 [1.14-2.65]). 47 
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Conclusion: People with higher scores for ADH, aggression/hostility and 48 
anxiety/neuroticism are at higher risk of NMPDU. Sociability appeared to protect from 49 
NMPDU of sedatives/sleeping pills and anxiolytics.  50 
Key words: NMPDU, personality traits, young men, Switzerland. 51 
 52 
 53 
 54 
 55 
 56 
 57 
 58 
 59 
 60 
 61 
 62 
 63 
 64 
 65 
 66 
5 
 
 
 
INTRODUCTION 67 
Prescription drugs such as opioid analgesics, sedatives, anxiolytics and stimulants are 68 
essential pharmacological agents in the treatment of acute and chronic pain, insomnia, 69 
anxiety, attention-deficit hyperactivity disorder (ADHD) and other psychiatric disorders.
1
 70 
However, management of these medicines is complicated by their potential for abuse or 71 
dependence
1, 2
. Similarly, non-medical prescription drug use (NMPDU) can occur and may 72 
even outnumber illicit drug use, e.g. because NMPD may be easier available and people 73 
may – often wrongly - assume that their use is not illegal. For example NMPDU is 74 
positively associated with prescribing patterns
3, 4
, which can be misperceived as a legal 75 
dispensation of these drugs. 76 
 77 
NMPDU involves the use of prescription drugs without a prescription or in ways not 78 
recommended by a doctor.
1, 5
 The motives of misuse are generally self-medication and 79 
recreational use (e.g. experimentation, ‘getting high’).6 NMPDU is on the rise in the United 80 
States (US)
1, 2
 and is becoming a growing public health problem.
7
 Several forces are 81 
apparently driving increases of NMPDU: marked increases in the numbers of prescriptions; 82 
internet access to prescription drugs as an easy new source of supply; and changes in drug 83 
formulation and prescribing practices that may lead to a greater risk of diversion and abuse.
8
 84 
In 2007, non-medical prescription opioids were second only to cannabis as the most 85 
frequently used illegal drug in the US;
9
 and in 2010, 3.6% of those aged 12 or older were 86 
current users of illicit drugs other than cannabis, with the majority of them being non-87 
medical users of psychotherapeutic drugs.
9, 10
 Young adults are now misusing prescription 88 
drugs at higher rates than all other illegal drugs with the exception of cannabis.
7
  89 
 90 
Most research has been undertaken in the US and focused on the most misused drug classes 91 
(i.e. opioid analgesics, sedatives/sleeping pills, anxiolytics and stimulants). However, there 92 
are only few studies outside the US, particularly in Europe. For this reason, the present 93 
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study looks at NMPDU among twenty-year-old men in Switzerland, which may serve as a 94 
role country for established market economies in Europe.  95 
 96 
A major aim of the present study is to look at personality traits of NMPD users. Personality 97 
traits (defined as “individual differences in the tendency to behave, think, and feel in certain 98 
consistent ways”11) have been shown to be associated with substance use.10, 12 For example, 99 
anxiety and sensation seeking (SS) are related to high and problematic substance use 100 
behaviors
13, 14
, and higher levels of SS seem to be associated with higher risks for an early 101 
onset of substance use and polysubstance use.
15
 Little is known, however, about personality 102 
traits of NMPD users?  Are NMPD users ‘normal’ individuals who overcome sometimes 103 
stressful situations with NMPDU, or do they show a profile that resembles users of other 104 
illicit substances? The answer to this question could enable early detection of particularly 105 
risky NMPDU.  106 
A recent study 
16
 of the National Epidemiological  Survey on Alcohol and Related 107 
Conditions (NESARC) indicated a shared, gender invariant liability to NMPDU and other 108 
forms of externalizing psychopathology such as other substance use disorders, as well as 109 
antisocial behaviors.  It is crucial to identify the risk profiles of substance use or abuse.
12
 110 
Substance users’ personalities form part of those risk profiles. Knowledge about personality 111 
factors can be used to design intervention and prevention strategies.
17
 Thus, this study will 112 
provide information concerning personality traits and NMPDU. 113 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       114 
The present study also goes beyond earlier studies by looking at drug classes commonly not 115 
under study: 1) beta blockers (which may be misused for their anti-tremor and, perhaps to a 116 
lesser degree, anti-anxiety effects)
18
, and 2) the antidepressants widely used against 117 
symptoms of depressive disorders and increasingly to treat anxiety disorders.
19
  Moreover, 118 
these two substances are among those used by healthy individuals in an attempt to enhance 119 
their cognitive function, such as increased concentration and focus for a specific task (or 120 
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reduce anxiety and fear), particularly by students in connection with exams.
20, 21
 An 121 
association with a fear subfactor of internalizing behaviours has been shown for NESARC.
16  122 
 123 
Commonly, research focused only on personality traits that were known to show higher 124 
risks for substance use (e.g. SS, anxiety). Personality traits which may have protective 125 
effects have rarely been studied. In addition to SS and anxiety/neuroticism, the present study 126 
therefore includes sociability and aggression/hostility, which have been associated with 127 
substance use in adolescents and young adults.
22
 It also includes attention 128 
deficit/hyperactivity (ADH) because sufferers of attention deficit/hyperactivity disorder 129 
(ADHD) were significantly more likely to develop disorders involving abuse/dependence 130 
for nicotine, alcohol, marijuana, cocaine, and other substances.
23
 An aim of the present 131 
study therefore is to investigate whether these personality traits not only play a role in heavy 132 
legal substance use and illicit drug or polysubstance use of e.g. cannabis, cocaine, heroin, 133 
but also in NMPDU.  134 
 135 
The few studies on NMPDU and personality factors have commonly looked at only one 136 
personality trait or on personality traits which were expected to have a detrimental impact 137 
on substance use. The link between a single personality trait and a single drug does not 138 
allow to study whether there is an overarching personality trait related to all non-medical 139 
prescription drugs, or whether different personalities choose different drugs. Furthermore, 140 
most studies on NMPDU focused on opioid analgesics, stimulants, sedatives and 141 
anxiolytics.
9, 10
 and were conducted in the US, where factors such as availability and 142 
prescribing practices are different from those in Europe. Thus high and increasing 143 
prevalence rates may not be mirrored and be related to more particular or “extreme” 144 
personality profiles. The present study therefore aimed to assess the relationships between 5 145 
specific personality traits (SS, attention-deficit/hyperactivity (ADH), anxiety/neuroticism, 146 
aggression/hostility and sociability) and 6 NMPDU (opioid analgesics, sedatives/sleeping 147 
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pills, anxiolytics, antidepressants, beta-blockers and stimulants) in Switzerland. We 148 
hypothesize that personality traits such as SS, ADH, anxiety/neuroticism, 149 
aggression/hostility and sociability would be significantly associated with NMPDU, but also 150 
that different personality traits would be related with different NMPDs. 151 
 152 
153 
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METHODS 154 
2.1. Sample 155 
Data came from the Cohort Study on Substance Use Risk Factors (C-SURF), a longitudinal 156 
study designed to assess the substance use patterns of young Swiss men and the related 157 
consequences. Enrolment took place between August 2010 and November 2011 in 3 of 6 158 
national Swiss army recruitment centers, located in Lausanne (French-speaking), Windisch 159 
and Mels (German-speaking). These cover 21 of 26 Swiss cantons. Attending army 160 
recruitment is compulsory, so virtually all men around 20 years-old (20±1.22) were 161 
available for inclusion in the study. 162 
The study was conducted outside the army context. Questionnaires in French or German (cf 163 
http://www.c-surf.ch/en/30.html) were sent to the 7,563 private addresses of those who gave 164 
written consent to participate. Of these, 5,990 (79.2%) returned a completed baseline 165 
questionnaire. Participants (n = 213, 3.5%) who omitted variables of interest were excluded 166 
(final sample n = 5,777). As had been shown in a previous study
24
, there was a certain 167 
amount of non-response bias, but this was often small and went in different directions. For 168 
the Francophone sample, for example, there were more alcohol abstainers among non-169 
respondents (11.6%) than respondents (11.2%), but there were more non-smokers (63.4%) 170 
among respondents than non-respondents (49.8%), and this was found for cannabis non-171 
users too (respondents, 64.8%; non-respondents, 58.0%)
24
. For the analysis of non-response 172 
bias, a very short five-minute questionnaire containing questions on demography, alcohol, 173 
tobacco and cannabis use was administered to all conscripts going through the recruitment 174 
procedures. It yielded a response rate of 94%. Unfortunately, the brevity necessary to ensure 175 
a high response rate from non-participants in the cohort study meant that no questions about 176 
NMPDU were asked in this very short questionnaire. Given the small differences for the 177 
others drugs assessed, we did not expect a major non-response bias for NMPDU. 178 
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2.2. Study protocol 179 
The study protocol (Protocol No 15/07) was approved by Lausanne University Medical 180 
School’s Clinical Research Ethics Committee. 181 
2.3.  Hypotheses 182 
We hypothesized that personality traits such as SS, ADH, anxiety/neuroticism, 183 
aggression/hostility and sociability would be significantly associated with NMPDU in 184 
general, but not necessarily all traits with all types of NMPDU. We hypothesize that SS will 185 
be significantly associated with all NMPDU due to mainly recreational purposes (i.e. 186 
experimentation or getting high) for people high on SS. Other personality traits, however, 187 
may have differential associations with different types of drugs because of their use for self-188 
medication, e.g. we hypothesize that anxiety/neuroticism is associated with anxiolytics and 189 
antidepressant but not with stimulants, whereas stimulants are more often used by people 190 
high on ADH.  191 
 192 
2.4. Measurements  193 
2.2.1. Non-Medical Prescription Drug Use (NMPDU) 194 
NMPDU was described to participants as use of prescription drugs without a prescription or 195 
in ways not recommended by a doctor. 196 
Frequency of NMPDU over the last 12 months was assessed for 6 drug classes (opioid 197 
analgesics, sedatives/sleeping pills, anxiolytics, antidepressants, beta blockers and 198 
stimulants). Examples were given for each class: a) sedatives/sleeping pills, e.g. 199 
benzodiazepines (Dalmadorm®, Rohypnol®), zopiclone or zolpidem (Imovane®, 200 
Stilnox®), chloral hydrate or barbiturates; b) anxiolytics, e.g. benzodiazepines (Valium®, 201 
Xanax®, Librax®) or muscle relaxants; c) opioid analgesics excluding aspirin and 202 
paracetamol, e.g. codeine (Benylin®), opiates (fentanyl, hydrocode) or buprenorphine 203 
(Tamgesic®); d) antidepressants, e.g. Fluoxetine®, Remeron®; e) stimulants, e.g. 204 
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amphetamine sulfate, atomoxetine or methylphenidate; and f) beta-blockers, e.g. 205 
propranolol, atenolol or metoprolol. Respondents answered on an eight-point scale (from 206 
‘never’ to ‘4 times per week or more’). The frequency of NMPDU was dichotomized as 207 
use/no use in the past 12 months. NMPDU prevalence was first calculated for the use of (at 208 
least) any one class of drug and then separately for each of the 6 classes. These data were 209 
the dependent variables. 210 
2.2.2. Personality traits 211 
1) Sensation seeking (SS) has been defined as a strong need for varied, novel and stimulated 212 
experiences, and willingness to take risks for the sake of them
25
. This study used the brief 213 
sensation seeking scale (BSSS)
26
 – an 8-item measurement of impulsive SS pertaining to the 214 
need for excitement, unpredictability and novelty, as well as the tendency to act quickly 215 
without thinking. Participants answered on a five-point scale (from 1 ‘strongly disagree’ to 216 
5 ‘strongly agree’). A SS global score was calculated by averaging the 8 items. Scores were 217 
dichotomized as below the median, or equal to the median of 3.12 or above, and coded 218 
‘low’ or ‘high’, respectively. Cronbach’s α of the present study was 0.81. 219 
2) Adult Attention Deficit/Hyperactivity (ADH) 220 
ADH was measured like the adult attention deficit/hyperactivity disorder (a disorder 221 
including symptoms of inattention, impulsivity, hyperactivity and associated impairments in 222 
multiple domains of functioning)
27
, using a 6-item screener version of the attention deficit 223 
syndrome adult self-report scale (ASRS).
28
 Participants answered on a five-point scale (from 224 
0 ‘never’ to 4 ‘very often’). Responses were summed to obtain a global score ranging from 225 
0 to 24.
29
 Scores were dichotomized as below the median, or equal the median of 5 or 226 
above, and coded ‘low’ and ‘high’, respectively. Our study did not use ADH as a disorder 227 
diagnosis, but as a screener of the attention deficit/hyperactivity personality trait. 228 
Cronbach’s α of the present study was 0.80. 229 
3) Aggression/hostility, anxiety/neuroticism and sociability 230 
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The 3 personality dimensions of aggression/hostility, anxiety/neuroticism and sociability 231 
were measured using the Zuckerman-Kuhlmann personality questionnaire. 
30
 Each 232 
dimension was assessed using a 10-item subscale in which participants answered true or 233 
false. For each of the 3 personality dimensions, the scale was first scored by summing the 234 
items ranging from 0 to 10 for each subscale. Again, for each subscale, scores were 235 
dichotomized as below the median, or equal to or above the median, and coded ‘low’ and 236 
‘high’, respectively. The medians were 1 for anxiety/neuroticism, 4 for aggression/hostility 237 
and 6 for sociability. Cronbach’s α of the present study were 0.62, 0.70 and 0.65 for 238 
aggression/hostility, anxiety/neuroticism and sociability, respectively. 239 
2.2.3.  Covariates 240 
Demographic covariates included age, relationship status (coded ‘single’ or ‘other’), 241 
educational level (coded ‘primary’, <10 years of schooling; ‘secondary’, 10–12 years; 242 
‘tertiary’, 13 years or more), current living arrangements (coded ‘living with family/couple’ 243 
or ‘alone/orphanage/foster home/homeless’), and financial independence, i.e. whether 244 
respondents were able to provide for themselves financially (coded ‘totally independent’, 245 
‘partially independent’ and ‘totally dependent’).  246 
2.2.4. Statistical analysis 247 
All analyses were performed using Stata version 12. Analyses include descriptive 248 
demographic characteristics, followed by logistic regressions. First, associations between 249 
each personality trait and each type of NMPDU, and then with at least any one NMPDU, 250 
were presented by crude odds ratios (OR). The same models were repeated adjusting for 251 
other socio-demographic variables. Finally, we fitted 7 multiple logistic regression models, 252 
predicting each of the NMPDU and adjusting for all personality traits and covariates. 253 
13 
 
 
 
With regard to the sample size, we estimated that for a type 1 error of 5% and a power of 254 
80%, 4,221 participants would be needed to detect an OR of 1.5. This OR corresponds to a 255 
small effect size
31
 under the assumption that the response probability (dependent variable, 256 
i.e. NMPDU is around 5%) and the independent variable of interest (i.e. personality traits 257 
with a median split) are correlated with control variables by R-squared of 0.20. Thus, our 258 
sample size was more than sufficient to test small effect sizes given that the prevalence of 259 
the corresponding NMPDU was not too low.  260 
For a dependent variable with a prevalence of 1%, only medium effect sizes (OR=2.5 
31
) can 261 
be tested. Under the same assumptions as above, 3,116 participants would be needed. Pass 262 
11 software (PASS 11. NCSS, LLC. Kaysville, Utah, USA. www.ncss.com) was used to 263 
calculate sample sizes. Pass 11 uses the algorithm described by Hsieh, Block, and Larsen 264 
(1998).
32
   265 
266 
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 267 
RESULTS 268 
3.1. Descriptive data 269 
Table 1 summarizes the demographic covariate study variables, descriptive data of each 270 
personality trait assessed and NMPDU. Mean age was 20 (SD 1.22).  271 
A total of 51.8% of participants showed high for SS, 57.0% showed high for ADH, 57.9% 272 
showed for aggression/hostility, 75.1% showed high for anxiety/neuroticism and 61.8% 273 
showed high for sociability.  274 
Of 5,777 participants, 616 (10.7%) reported at least one NMPDU in the last 12 months. 275 
More specifically, 389 (6.7%) respondents had used opioid analgesics, 171 (3.0%) 276 
sedatives/sleeping pills, 153 (2.7%) anxiolytics, 109 (1.9%) stimulants, 51 (0.9%) 277 
antidepressants and 30 (0.5%) beta blockers. 278 
 279 
Insert Table 1 about here 280 
3.2. Logistic regression of NMPDU on personality traits 281 
Table 2 shows the association between personality trait and NMPDU adjusting for age, 282 
relationship status, educational level, current living arrangements and financial 283 
independence. 284 
Concerning the association between each personality trait and each type of NMPDU, results 285 
(part a) showed that ADH, anxiety/neuroticism, aggression/hostility, and SS were 286 
significantly positively related with any NMPDU, but these associations varied with 287 
different drug classes. Adjustment by covariates did not change effects (data without 288 
covariates adjustment not shown).  289 
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Part b of Table 2 shows the models for each of the NMPDU adjusting of all personality 290 
traits and covariates simultaneously. Multiple adjustments of all personality traits did not 291 
alter the findings for models taking personality traits separately. ADH, anxiety/neuroticism 292 
and aggression/hostility are positively linked to almost each NMPDU (except ADH and 293 
anxiety/neuroticism for beta-blockers, and aggression/hostility for antidepressants). Only 294 
aggression/hostility was significantly and positively associated with beta blockers. Those 295 
who reported high ADH, anxiety/neuroticism and aggression/hostility, had ORs of 1.47 296 
[1.22-1.76] to 1.86 [1.47-2.35] of reporting at least one NMPDU. SS was only significantly 297 
positively associated with any NMPDU and with NMPDU of stimulants with OR of 1.24 298 
[1.04-1.48] and 1.74 [1.14-2.65], respectively. Sociability was significantly negatively 299 
associated with sedatives/sleeping pills and anxiolytics, with OR of 0.70 [0.51-0.96] and 300 
0.64 [0.46-0.90], respectively.  301 
Insert Table 2 about here 302 
303 
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DISCUSSION 304 
Our results showed a 10.7% prevalence for any NMPDU in the last 12 months (see Section 305 
3.3 above for details), which seems to be lower than those in the US
10, 33
 but were 306 
comparable to those in Ontario, Canada 
34
 at least as regards of opioid analgesics. Such 307 
differences observed in NMPDU rates between the US and our study could be influenced by 308 
differences in prescribing practices , drug access and availability, the distinct dynamics of 309 
adolescent drug cultures (e.g. as related to varying subcultural norms related to substance 310 
use), or potential substitution effects involving alternative (legal or illegal) drugs.  311 
 312 
Nevertheless, Swiss prevalence rates are not negligible. For the 12 months prior to our 313 
study, the sample’s prevalence for alcohol was 92.9%, followed by tobacco (45.7%) and 314 
cannabis (30.7%). After cannabis, the next highest prevalence for an illicit drug was ecstasy 315 
(3.7%), followed by cocaine (3.2%).
35
 Our results confirm that NMPDU by males in 316 
Switzerland ranks just after alcohol, tobacco and cannabis use. Further, NMPDU of opioid 317 
analgesics alone had a higher prevalence than any illicit drug except cannabis.  This 318 
indicates that NMPDU may become a growing public health concern that needs monitoring 319 
not only in the US, but also in Europe. Furthermore, several US studies showed that 320 
NMPDU was more prevalent in women than in men. Thus, prevalence rates may be 321 
underestimated in the present study which only included  men. 322 
 323 
Several studies
6, 7, 9, 36
 including both men and women suggested that the ranking of 324 
NMPDU among other substances may hold for both genders. Therefore, the high prevalence 325 
of NMPDU among men compared with other illicit drugs coupled with the absence of 326 
women in the present study, for which often even higher prevalence rates of NMPDU (but 327 
lower rates for other illicit drugs) were found, may even mean that prevalence rates 328 
including both women and men could be closer to that of cannabis. However, clearly the 329 
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potential for gender differences needs confirmation by further studies in Switzerland 330 
including women.  331 
 332 
The study’s primary aim was to investigate whether personality traits (i.e. SS, ADH, 333 
aggression/hostility, anxiety/neuroticism and sociability) were related to NMPDU. 334 
Personality variables are important distal factors with direct and indirect effects on the 335 
development of substance use.
22, 37
  Although significance levels were partly reduced in 336 
multiple trait comparison, the findings did not substantively change compared with models 337 
using only single personality traits. It is therefore possible to look at specific relationships 338 
between personality and NMPDU separately. This is important for studies that do not have 339 
multiple measures of personality at hand, which was the case with many earlier studies so 340 
far.  341 
 342 
Our main findings were that individuals with high ADH, aggression/hostility and 343 
anxiety/neuroticism scores were more likely to be using non-medically prescribed opioid 344 
analgesics, sedatives/sleeping pills, anxiolytics or stimulants. Their use may therefore be 345 
more strongly linked to self-medication because of their anti-anxiety and anxiolytic/sedative 346 
effects than to recreational use.  For example, pain relief, i.e. self-medication was the most 347 
reported motive for NMPDU of opioids in other studies.
38, 39
  Although the present study did 348 
not measure motives for use, it indirectly supports the hypothesis of NMPDU being more 349 
strongly related to self-medication than solely recreational use (experimentation or ‘getting 350 
high’).6, 39  NMPDU had a rather “problematic” personality profile, which is also consistent 351 
with the fact that self-medication occurs in a context of self-regulation of vulnerabilities – 352 
primarily difficulties in regulating effects, self-esteem, relationships and self-care.
38
  353 
 354 
Many studies on substance use showed an association between heavy alcohol, tobacco or 355 
cannabis use, polysubstance use, and misuse among people high on SS
15
. Our results 356 
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showed that SS is solely associated with NMPDU for stimulants but not with other 357 
NMPDU, further strengthening our self-medication hypothesis for the other NMPDs. This is 358 
consistent with the finding Low and Gendaszek 
40
, that individuals with high levels of 359 
sensation-seeking were more likely to use stimulants. We assume that stimulants are used 360 
by sensation seekers in a more recreational way looking for higher arousal levels, whereas 361 
they do not use e.g., sedatives/sleeping pills or opioids analgesics to sedate their arousal, or 362 
to self-medicate their anxiety. Sensation seekers are generally interested in novel 363 
experiences which may be enhanced by stimulants. Further studies are needed to look more 364 
closely into the motives related with the use of different NMPD classes, and particularly 365 
among sensation seekers.  366 
 367 
In contrast to other studies that have mostly looked at personality traits associated with 368 
higher risks of substance use, the present study found sociability to be negatively associated 369 
with NMPDU, specifically to sedatives/sleeping pills and anxiolytics. Due to the cross-370 
sectional nature of this study, no causal conclusions can be drawn. We can only speculate 371 
about potential explanations of this negative association, because there are almost no studies 372 
on the association between sociability and NMPDU that could further substantiate our 373 
interpretation. Studies looking at the link between sociability and substance use other than 374 
NMPDU have not yielded consistent findings. Some studies reported positive associations, 375 
i.e. higher levels of sociability being associated with higher substance use levels;
37, 41
 others 376 
have found that less sociability is related to more substance use.
42
 In these studies, substance 377 
use has often been studied as a combination of alcohol, tobacco and cannabis. Therefore, 378 
neither could be determined whether associations varied across substances, nor was 379 
NMPDU included in these studies. Hampson and colleagues found that higher levels of 380 
sociability predicted the intention to use alcohol
43
, but did not predict the intention to smoke 381 
cigarettes.
44
 Alcohol use is more prevalent, and perceived to be a less deviant and more 382 
socially acceptable behavior, than using other substances. Although as stated above, we can 383 
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only speculate about findings due to the lack of research on NMPDU and sociability, 384 
NMPDU may be a less socially accepted behavior compared with alcohol use. It is clearly 385 
less prevalent than alcohol use or even tobacco use. Thus, particularly people high on 386 
sociability may disapprove NMPDU due to being a more deviant and socially unaccepted 387 
behavior. As this is only a statistical association, it does not mean that all people with 388 
medium or low sociability approve NMPDU use. They are just more likely to use NMPD 389 
compare with people high on sociability.  390 
This study has several limitations. First, study data are self-reported and do not use an 391 
objective criterion such as a urine test to confirm findings. Although such data on risky 392 
behaviors and substance use are generally considered valid
4545
, self-reported surveys could 393 
introduce various forms of bias, including recall bias, pressure to give desirable answers and 394 
non-response bias. Therefore, adding more objective measures like a urine test would have 395 
been good on the one hand. On the other hand people who want to avoid socially 396 
undesirable answers may also not be favorable to provide urine tests. Second, this study 397 
comprised only men and cannot therefore be generalized to women, although they are 398 
known to misuse prescription drugs too. Third, because the data are cross-sectional, 399 
causality cannot be determined. Fourth, we did not analyze the differences between poly- or 400 
single-substance users, but only assessed NMPDU differences between 1) NMPDU classes, 401 
and 2) any NMPDU across several NMPD classes. Poly- versus single-substance NMPD 402 
users may have different personality profiles. Finally, several research questions on motives 403 
for NMPDU could not be answered, because they were not measured. Particularly direct 404 
questions on whether substances were used for self-medication or just for ‘getting high’ 405 
were missing. More longitudinal data are needed, such as on whether NMPDU induces 406 
anxiety and neuroticism, or vice versa. Despite these limitations, this study is among the 407 
first to document associations between NMPDU and several personality traits, and this for a 408 
country outside the US. 409 
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This study found NMPDU prevalence lower than in the US; however, monitoring of 410 
NMPDU should be done in Switzerland because, as like the US, NMPDU prevalence rates 411 
are above those for all illicit drugs except cannabis and thus are already a significant public 412 
health theme. The present study used a wider spectrum of both NMPDU classes and 413 
personality traits than most other studies, thus extending prior research on the association of 414 
personality on the development of substance use to NMPDU providing more information 415 
about NMPDU. The study suggests that NMPDU was on the one hand consistently 416 
positively (though not always significantly so) associated with personality traits such as 417 
ADH, a more aggressive or hostile personality, or a more anxious personality. On the and 418 
sensation seeking was specifically positively associated with stimulant use and sociability 419 
showed even significant negative associations. This study suggests that potentially 420 
problematic users could be screened by personality traits. Thus, the present study has 421 
important clinical implications and could be used to inform intervention agencies to develop 422 
measures for preventing NMPDU in young adults. 423 
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Table 1. Descriptive data (n = 5777) 
Demographic variables Independent: Personality traits Dependent: NMPDU 
Variables n (% ) Variables n (% ) Variables n (% ) 
Educational level  SS    
Primary (<10 years) 2780 (48.1) Low 2786 (48.2)  Any drug 616 (10.7) 
Secondary (10–12 years) 1530 (26.5)   High 2991 (51.8) Opioid analgesics  389 (6.7) 
Tertiary (≥13 years) 1467 (25.4)   
Sedatives/sleeping 
pills  171 (3) 
Relationship status  ADH  Anxiolytics  153 (2.7) 
Single  5487 (95) Low 2485 (43) Stimulants  109 (1.9) 
Other 290 (5) High 3292 (57) Antidepressants  51 (0.9) 
Current living arrangements  Aggression/hostility   Beta-blockers  30 (0.5) 
Family/couple  5313 (92) Low 2434 (42.1)   
Other (alone/orphanage/foster 
home/homeless) 464 (8) High 3343 (57.9)   
  Anxiety/neuroticism    
  Low 1440 (24.9)   
  High 4337 (75.1)   
  Sociability    
  Low 2208 (38.2)   
  High 3569 (61.8)   
ADH, attention deficit–hyperactivity; NMPDU, non-medical prescription drug use; SS, sensation seeking. 
  
 
Table 2. Associations between personality traits and NMPDU (n = 5777) 
 
Associations between each personality trait and each NMPDU 
 Use of any drug Sleeping pills  Painkillers  Stimulants Anxiolytics Antidepressants Beta-blockers  
Personality traits AOR† (95%CI) AOR† (95%CI) AOR† (95%CI) 
AOR† 
(95%CI) 
AOR† 
(95%CI) AOR† (95%CI) AOR† (95%CI) 
SS 
1.34 (1.14–
1.60)** 
1.23 (0.90–
1.67) 
1.21 (0.98–
1.49) 
2.02 (1.34–
3.04)** 
1.25 (0.90–
1.74) 1.04 (0.60–1.82) 
0.71 (0.34–
1.47) 
ADH 
1.65 (1.38–
1.98)** 
2.41 (1.69–
3.44)** 
1.41 (1.14–
1.76)** 
2.24 (1.45–
3.46)** 
2.50 (1.71–
3.65)** 
2.52 (1.31–
4.85)** 
1.79 (0.81–
3.94) 
Aggression/hostility 
1.70 (1.42–
2.04)** 
1.90 (1.35–
2.67)** 
1.67 (1.33–
2.09)** 
2.88 (1.80–
4.62)** 
2.59 (1.76–
3.81)** 
2.11 (1.12–
3.98)* 
2.90 (1.18–
7.11)* 
Anxiety 
2.03 (1.61–
2.56)** 
2.41 (1.52–
3.82)** 
2.00 (1.49–
2.66)** 
2.11 (1.22–
3.65)** 
2.37 (1.46–
3.85)** 
5.35 (1.66–
17.21)** 
3.00 (0.91–
9.90) 
Sociability 
0.89 (0.75–
1.06) 
0.62 (0.46–
0.85)** 
1.04 (0.84–
1.29) 
0.86 (0.59–
1.27) 
0.58 (0.42–
0.80)** 0.87 (0.49–1.52) 
0.60 (0.29–
1.24) 
 Multiple logistic regression of NMPDU on personality traits modeled simultaneously  
Personality traits 
Any NMPDU Sleeping pills Painkillers Stimulants Anxiolytics Antidepressants 
Beta-
blockers  
AOR‡ (95%CI) 
AOR‡ 
(95%CI) 
AOR‡ 
(95%CI) 
AOR‡ 
(95%CI) 
AOR‡ 
(95%CI) AOR‡ (95%CI) 
AOR‡ 
(95%CI) 
SS 1.24 (1.04–
1.48)* 
1.10 (0.80–
1.52)  
1.11 (0.90–
1.38) 
1.74 
(1.14–
2.65)** 
1.11 
(0.79–
1.55)  
0.88 (0.50–
1.55) 
0.64 (0.30–
1.34) 
ADH  1.47 (1.22–
1.76)** 
2.08 (1.45–
3.00)** 
1.29 (1.03–
.61)*  
1.84 
(1.18–
2.87)**  
2.11 
(1.44–
3.11)**  
2.26 (1.16–
4.38)* 
1.61 (0.72–
3.60) 
Aggression/hostility 1.54 (1.28–
1.85)**  
1.70 (1.21–
2.40)** 
1.54 (1.23–
1.93)**  
2.48 
(1.54–
4.00)**  
2.32 
(1.57–
3.43)** 
1.88 (0.99–
3.56) 
2.75 (1.11–
6.79)* 
Anxiety 1.86 (1.47–
2.35)**  
1.99 (1.25–
3.17)** 
1.88 (1.40–
2.51)**  
1.79 
(1.03–
3.21)* 
1.87 
(1.14–
3.06)*  
4.61 (1.42–
14.92)* 
2.37 (0.71–
7.93) 
Sociability 0.96 (0.80–
1.14) 
0.70 (0.51–
0.96)* 
1.13 (0.91–
1.40) 
0.90 
(0.61–
1.34) 
0.64 
(0.46–
0.90)* 
1.06 (0.60–
1.88) 
0.71 (0.34–
1.48) 
†Adjusted for age, relationship status, educational level, current living arrangements and financial independence, *P < 0.05, 
**P < 0.01. ‡Adjusted for age, relationship status, educational level, current living arrangements and financial independence 
with simultaneous personality traits, *P < 0.05, **P < 0.01. Non-users serve as the reference group. ADH, attention deficit–
hyperactivity; AOR, adjusted odds ratio; CI, confidence interval; NMPDU, non-medical prescription drug use; SS, sensation 
seeking. 
 
